Increasing Prevalence Of Coronary Heart Disease Is Augmenting The Growth Of The Coronary Stents Market
Coronary stents are typically made from metal mesh, a stent is placed into an artery to enlarge the opening of the artery, also known as an angiocatheca, after a surgical procedure to widen the artery known as a Percutaneous coronary intervention or, more commonly, an angioplastectomy. Performed with local anesthesia and minimal sedation, an angioplastectomy usually takes less than an hour and uses no major surgical incisions. Another popular technique for the placement of coronary stents involves the use of drug-eluting stents.
The
growing prevalence of coronary heart disease in India is propelling the growth
of the India coronary stents market. According to the World Health Organization
(WHO), cardiovascular disease-account for over a quarter (26%) of these deaths.
15% of the population smoke tobacco, 4.3 liters of pure alcohol consumed per
person, and Just over a fifth (21.1%) have hypertension which can increase the
risk of heart attack, heart failure, kidney disease, or stroke. Additionally,
the high adoption of stents in the treatment of a cardiovascular blockage in
the country is again fostering the growth of the India coronary stents market.
The lack of centers that offer PCI and primary PCI procedures coupled with the
low accessibility to the medical facilities especially across rural areas is
projected to restrict the growth of the India coronary stents market.
Key Developments:
1. In February 2018, Medtronic plc
has announced the U.S. Food and Drug Administration (FDA) approval and U.S.
launch of the Resolute Onyx 2.0 mm Drug-Eluting Stent (DES)—the smallest sized
DES on the market.
2. In June 2017, OrbusNeich has
announced the launch of its Sapphire percutaneous coronary angiography balloon
dilatation catheters (Sapphire II PRO and Sapphire NC Plus) following their
recent 510k clearance by the FDA.
3. In February 2019, Biotronik has
received premarket approval from FDA for its Orsiro ultrathin drug-eluting
stent intended for use in percutaneous coronary intervention procedures
4. In March 2018, SMT (Sahajanand
Medical Technologies), the manufacturer of cardiac stents in India, announces a
strategic partnership with Cordis, Cardinal Health’s interventional vascular
business. The new partnership with SMT in India provides Cardinal Health access
to the fast-growing Indian cardiology market, as the latter marks its entry
into the Indian market.
5. In September 2017, iVascular SLU
announced that it has received approval for selling its coronary and peripheral
products in India. iVascular product portfolio was produced with advanced
technologies to enhance patient outcomes and provide physicians with the
solution for the challenges that they’ve meet daily.
Comments
Post a Comment